[ad_1]
The global genome engineering market was assessed at US $ 2,582.7 million in 2016 and is forecast to record a magnificent CAGR of 14.3% over the forecast period (2017-2025).
The introduction of novel technologies in genome engineering is a fundamental aspect accelerating the growth of the global genome engineering market. In 2017, Synthego Corporation launched its CRISPRevolution Gene Knockout Kit (GKO), featuring the first guaranteed CRISPR gene editing solution. The new Synthego kits rapidly modify difficult-to-edit human hematopoietic stem cells, as well as primary T cells, cost-effectively.
Get a FREE sample PDF including COVID-19 impact analysis: https://www.coherentmarketinsights.com/insight/request-sample/1262
Global Genome Engineering Market: Outlook
Genome engineering is the synthetic assembly of complete chromosomal DNA that is more or less derived from natural genomic sequences. There are two types of gene therapy, namely, Ex-Vivo Gene Therapy and In-Vivo Gene Therapy. In ex vivo gene therapy, genes are transferred into cultured cells and then reintroduced into the patient. In contrast, in in vivo gene therapy, genes are delivered directly into cells of a particular tissue. Key companies such as CRISPR Therapeutics AG, Editas Medicine, Inc. and Intellia Therapeutics, Inc. are focusing on the development of in vivo and ex vivo gene therapies. The main techniques used in genome engineering are CRISPR, TALEN and ZFN. CRISPR (CRISPR-Cas9). Additionally, there are new genome editing tools available for researchers to edit parts of the genome by adding, removing, or altering sections of the DNA sequence. In which, CRISPR is an accurate, faster, and cheaper technique for editing DNA compared to other methods such as TALEN and ZFN. Transcriptional activator-type effector nucleases (TALEN) is a technology widely used in gene editing in living cells. Zinc Finger Nucleases (ZFNs) are an artificial restriction enzyme that simplifies targeted genome editing by creating double-stranded breaks in DNA at user-specified locations.
LIMITED TIME OFFER – Hurry!
Get a buyer discount of up to 25% off any research report
Apply the promotional code “CHRISTMAS2020” and get an instant discount of USD 1000
Buy now this premium report to grow your business @ https://www.coherentmarketinsights.com/insight/buy-now/1262
Market dynamics: drivers
The increasing development of new technologies in genome engineering is expected to drive the growth of the global genome engineering market in the near future.
The introduction of new technologies in genome engineering by key market players is expected to drive the growth of the global genome engineering market during the forecast period. For example, in February 2018, Sangamo Therapeutics, Inc. received clinical trial authorization (CTA) from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its SB-FIX, a zinc finger nuclease ( ZFN) mediated in vivo. The genome editing treatment for hemophilia B. TCA has enabled the start of the first European in vivo genome editing study. In 2017, Integrated DNA Technologies, Inc. released the first variant of the Cas9 enzyme, which reduces off-target effects in CRISPR genome editing. The release of the latest variant of the Cas9 enzyme is an important step towards the therapeutic use of CRISPR. In 2017, scientists at the Salk Institute for Biological Studies modified CRISPR to epigenetically treat diabetes, kidney disease, and muscular dystrophy. They developed the latest version of the CRISPR / Cas9 genome editing technology, which allows for the activation of genes without creating breaks in DNA. Therefore, the advancement of technologies is expected to drive the growth of the global genome engineering market during the forecast period.
The global market for genome engineering was valued at US $ 2,582.7 Mn in 2016 and is expected to witness a CAGR of 14.3% during the forecast period (2017-2025).
Figure 1. Global Genome Engineering Market Share (%), by Technology, 2017-2025
Source: Coherent Market Insights Analysis (2017)
See press release for more information @ https://www.coherentmarketinsights.com/press-release/genome-engineering-market-to-surpass-us-85125-mn-threshold-by-2025-577
Increased strategic collaboration for genome engineering technologies by key players is expected to drive market growth in the near future.
Key market players are involved in various growth strategies, such as collaborations, agreements, and partnerships, in order to gain a competitive advantage in the market. For example, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, entered into a collaboration agreement with Sangamo Therapeutics Inc. to develop cell therapies designed to treat cancer. Under the agreement, Kite Pharma, Inc. will use Sangamo Therapeutics zinc finger nuclease (ZFN) gene editing technology to develop next-generation ex vivo cell therapies for the treatment of cancer. Additionally, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for engineering the CRISPR genome. In 2016, CRISPR Therapeutics and Bayer AG collaborated and formed a joint venture, Casebia Therapeutics, to develop CRISPR-based therapies in selected disease areas. Additionally, in 2017, Casebia Therapeutics partnered with CureVac AG. Under a collaboration agreement, CureVac will develop new Cas9 mRNA constructs with improved properties for gene editing applications. In 2015, AstraZeneca plc began research collaborations with The Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and the Broad Institute / Whitehead Institute to use their CRISPR technology for genome editing. These strategic collaborations between major key players and research institutes are expected to drive market growth in the near future.
Furthermore, increased funding and investments for the development and research of new genetic engineering technologies are expected to drive market growth. For example, in January 2018, the US National Institutes of Health (NIH) announced that they would award $ 190 million for genome-editing research. This new program, Somatic Cell Genome Editing, will fund biomedical researchers for the next six years. Support from leading research organizations like the NIH is expected to attract more researchers in this field, which can lead to advancements in technology and also help market growth.
Market dynamics: restrictions
The high cost associated with genome engineering technologies is expected to slow the growth of the global genome engineering market during the forecast period. For example, according to the fee schedule provided by the Yale Genome Editing Center, in 2018, it charges between $ 8,000 and $ 15,000 for gene editing facilities. The high cost associated with genome engineering facilities is expected to hamper market growth, especially in emerging economies such as India, Brazil and South Africa. Furthermore, genome engineering is a very complex technology and needs highly skilled researchers, limiting its adoption rate.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1262
Competitive landscape
Key players operating in the global genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis SA, and Merck Group.
Detailed segmentation:
- Global Genome Engineering Market, By Technology:
- Global Genome Engineering Market, By Application:
- Cell line engineering
- genetic engineering
- Global Genome Engineering Market, By End User:
- Biotechnology and pharmaceutical companies
- Research Institutes
- Organization of research contracts
Other related news:
CRISPR and CAS gene market, by product type, by application, by end-user and by region: size, participation perspective and opportunity analysis, 2018-2026
Single Cell Genome Sequencing Market, By Product, By Technology, By End User, And By Geography: Size, Share, Outlook, And Opportunity Analysis, 2018-2026
Digital Genome Market, By Product Type, By Application, By End User, And By Region: Size, Share, Outlook, And Opportunity Analysis, 2018-2026
About us:
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our large number of clients achieve transformational growth by helping them make critical business decisions. Our headquarters are in India, we have offices in the financial capital of the world in the US and sales consultants in the UK and Japan. Our client base includes players from various business verticals in more than 150 countries around the world. We pride ourselves on serving clients across the horizon, from Fortune 500 companies to nonprofits and startups looking to establish themselves in the marketplace. We excel in delivering unmatched actionable market intelligence across multiple industry verticals, including chemicals and materials, healthcare, and food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications, and automotive. We offer syndicated market intelligence reports, custom investigation solutions, and consulting services.
To learn more about us, visit our website: www.coherentmarketinsights.com
Contact:
Consistent market outlook
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
UK: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837
This content has been distributed through the CDN Newswire press release distribution service. For press release inquiries, please email us at [email protected].
